CIK 0001099219
MET METLIFE INC
Insider trading from SEC Form 4. Last filing Dec 18, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at METLIFE INC, scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 38Weak | sell 2 | DEBEL MARLENE EVP & Chief Risk Officer | $1.9M | 22,810 | -17% | - | |
| 43Moderate | sell 2 | Khalaf Michel President & CEO | $1.7M | 20,926 | -4% | - |
Congressional trades
3 trades in MET disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Alan Armstrong Senate · R-OK | Purchase | MET MetLife, Inc. Common Stock | $1,001 to $15k | Mar 27, 2026 | 116 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Partial sale | MET MetLife, Inc. Common Stock | $1,001 to $15k | Aug 6, 2025 | 37 days after the trade |
| Ritchie Torres House · D-NY | Sale | MET MetLife, Inc. Common Stock | $1,001 to $15k | Jul 11, 2025 | 40 days after the trade |
Transactions
The last 17 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 16, 2024 | HUBBARD ROBERT GLENN director | AGrant or award Common Stock | +579 | $82.74 | $48k | 96,410 | Dec 18, 2024 |
| Dec 16, 2024 | MCKENZIE DIANA director | AGrant or award Common Stock | +132 | $82.74 | $11k | 20,132 | Dec 18, 2024 |
| Dec 16, 2024 | Kennard William E director | AGrant or award Common Stock | +271 | $82.74 | $22k | 41,372 | Dec 18, 2024 |
| Dec 16, 2024 | KELLY EDWARD J III director | AGrant or award Common Stock | +232 | $82.74 | $19k | 35,523 | Dec 18, 2024 |
| Dec 16, 2024 | Johnson Jeh C. director | AGrant or award Common Stock | +33 | $82.74 | $2,730 | 5,069 | Dec 18, 2024 |
| Dec 16, 2024 | Herzog David L director | AGrant or award Common Stock | +39 | $82.74 | $3,227 | 25,340 | Dec 18, 2024 |
| Dec 16, 2024 | Hay Laura J director | AGrant or award Common Stock | +13 | $82.74 | $1,076 | 2,023 | Dec 18, 2024 |
| Dec 16, 2024 | Harris Carla A director | AGrant or award Common Stock | +16 | $82.74 | $1,324 | 6,801 | Dec 18, 2024 |
| Dec 16, 2024 | GRISE CHERYL W director | AGrant or award Common Stock | +536 | $82.74 | $44k | 86,541 | Dec 18, 2024 |
| Dec 13, 2024 | DEBEL MARLENE EVP & Chief Risk Officer | MOption exercise Common Stock | +13,107 | $34.33 | $450k | 121,614 | Dec 17, 2024 |
| Dec 13, 2024 | Khalaf Michel President & CEO | MOption exercise Common Stock | +26,138 | $45.91 | $1.2M | 521,725 | Dec 17, 2024 |
| Dec 13, 2024 | DEBEL MARLENE EVP & Chief Risk Officer | MOption exercise Common Stock | +9,703 | $45.91 | $445k | 131,317 | Dec 17, 2024 |
| Dec 13, 2024 | Khalaf Michel President & CEO | SOpen-market sale Common Stock | -20,926 | $82.84 | $1.7M | 500,799 | Dec 17, 2024 |
| Dec 13, 2024 | DEBEL MARLENE EVP & Chief Risk Officer | SOpen-market sale Common Stock | -22,810 | $82.88 | $1.9M | 108,507 | Dec 17, 2024 |
| Dec 13, 2024 | Khalaf Michel President & CEO | MOption exercise Employee Stock Option (Right to Buy)derivative | -26,138 | $0.00 | $0 | 0 | Dec 17, 2024 |
| Dec 13, 2024 | DEBEL MARLENE EVP & Chief Risk Officer | MOption exercise Employee Stock Options (right to buy)derivative | -13,107 | $0.00 | $0 | 0 | Dec 17, 2024 |
| Dec 13, 2024 | DEBEL MARLENE EVP & Chief Risk Officer | MOption exercise Employee Stock Options (right to buy)derivative | -9,703 | $0.00 | $0 | 0 | Dec 17, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- DEBEL MARLENEEVP & Chief Risk Officer
- GRISE CHERYL Wdirector
- HUBBARD ROBERT GLENNdirector
- Harris Carla Adirector
- Hay Laura Jdirector
- Herzog David Ldirector
- Johnson Jeh C.director
- KELLY EDWARD J IIIdirector
- Kennard William Edirector
- Khalaf MichelPresident & CEO
- MCKENZIE DIANAdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.